Table 1.

Summary of the eyelid-periocular skin basal cell carcinoma cases treated with ECT.

	Age (year)/gender	Periorbital localization	Other localization	Size of periocular tumor/s (mm)	Primary/recurrent/previous treatments	Route of Bleomycin administration	Type of electrode/average current(A)	Follow-up (month)	Results
1	44/M	upper eyelid		35 × 12 × 3	primary	it	row needle/3–5	16	CR
2	64 M	lower eyelid,	fronto-temporal region and cheek	43 × 27 × 1	recurrent/multiple surgeries, vismodegib	iv	hexagonal/4–6 row needle/2–5	36	CR
3	72/M	lower eyelid		10 × 10 × 1	recurrent/surgery	it	row needle/1.5–3	18	CR
4	71/M	medial canthal region		7 × 9 × 2	recurrent/surgery	it	row needle/7–10	16	CR
5	77/F	lower eyelid,	both hands, nose	13 × 10	recurrent after surgery	iv	hexagonal/4–6	21	CR
6	35/F	eyebrow		25 × 10	recurrent/surgery	iv	hexagonal/2–3	56	CR
7	11/F	upper eyelid, lower eyelid, both canthal regions	nose, perioral skin, frontotemporal area	6 × 8 ; 12 × 5	recurrent/surgery	iv	row needle/2–3	20	CR
8	80/F	both lower eyelids, medial canthi	head-neck, back	15 × 108 × 5	recurrent/surgery	iv	row needle/4–6	20	CR
9	62/F	lateral canthus, upper eyelid	head-neck, back	8 × 6  5 × 4 × 2	recurrent/surgery	iv	hexagonal/3–6	55	CR
10	72/M	lower eyelid, medial canthal region	head-neck, chest, upper extremities	7 × 5 × 3;  2 × 3 × 1	recurrent/surgery	iv	row needle/1,5–3	15	CR
11	86/M	lateral canthal region	trunk, head-neck, extremities	25 × 25	primary	iv	row needle/2–3	16	CR
12	65/M	medial canthal region	trunk, head-neck, extremities	14 × 14 × 2	primary	iv	row needle/1.5–3	15	CR

Basal cell carcinomas in other localizations were also treated with ECT. (CR: complete response; it: intratumoral; iv: intravenous).